MorphoSys AG
Semmelweisstrasse 7
Planegg 82152
Germany
49 89 899 27-0
https://www.morphosys.com
版塊: Healthcare
行業: Biotechnology
全職員工: 464
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman of Management Board, MD & CEO | 1.9M | 無 | 1965 |
| Dr. Lucinda Crabtree Ph.D. | CFO & Member of Management Board | 758.76k | 無 | 1979 |
| Ms. Charlotte Lohmann | Chief Legal and Human Resources Officer & Member of Management Board | 509.66k | 無 | 1970 |
| Mr. Klaus De Wall | Head of Accounting & Tax | 無 | 無 | 無 |
| Dr. Margit Urban | Head of Discovery Alliances & Technologies | 無 | 無 | 無 |
| Dr. Julia Neugebauer Ph.D. | Head of Investor Relations | 無 | 無 | 無 |
| Dr. Barbara Krebs-Pohl Ph.D. | Chief Business Officer | 無 | 無 | 無 |
| Dr. Günter Wellnhofer | Head of Technical Operations | 無 | 無 | 無 |
| Dr. Harald Watzka | Head of Alliance Management | 無 | 無 | 無 |
| Ms. Yen Ching Chua | Head of Clinical Operations | 無 | 無 | 無 |
描述
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
公司管治
截至 2024年5月1日 止，MorphoSys AG 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：3；董事會：1；股東權利：1；現金賠償：6。
